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Key Clinical Message
Sodium thiosulfate (STS), first-line treatment for calcific uremic arteriolopathy,
causes a mild asymptomatic acidosis in many patients. However, severe, life-
threatening acidosis out of proportion with the expected acid load of STS may occur,
potentially due to metabolism of STS to hydrogen sulfide.
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IN T RO D U C T ION

Calcific uremic arteriolopathy (CUA), or calciphylaxis, is
an inflammatory condition in which calcium deposits on
arteriolar vascular beds, leading to ischemia, cell damage,
and sometimes necrosis. Sodium thiosulfate (STS) has
emerged as a first-line treatment for CUA ulcers and necrosis, but much remains unknown about its metabolism
and toxicity. We present a case in which a patient developed severe metabolic acidosis with an anion gap following STS infusion, which was distinctly out of proportion
with the expected metabolic changes. Hydrogen sulfide is a
known metabolite of STS, and its role in hypoxia signaling
in vascular beds and its neutralization of reactive oxygen
species may contribute to the therapeutic role of STS. In
chronic kidney disease (CKD), levels of hydrogen sulfide
are reduced and restoring endogenous levels may be an
important mechanism of STS action. The toxicity profile
of hydrogen sulfide includes inhibition of mitochondrial
ATP production and extreme lactic acidosis, possible contributor to the metabolic acidosis with an anion gap. Still,
given the rarity of this reaction, some patients may possess
a metabolic phenotype that confers a predisposition to this
dangerous event.

Calcific uremic arteriolopathy is an inflammatory condition associated with end-stage renal disease (ESRD) in which
calcium salts deposit on arteriolar vascular beds, leading to
ischemia, cell damage, and possibly necrosis.1 CUA is positively associated with female sex, obesity, diabetes, protein
C deficiency, hyperphosphatemia, hypercalcemia, the use of
calcium-based phosphate binders, and warfarin use in patients requiring renal replacement therapy, but more cases are
being seen with normal calcium and phosphate levels due to
better standards of care.1 The incidence of CUA in ESRD
has been documented for 5.7 cases per 10 000 chronic hemodialysis patients in 2011 and is rising2; prevalence as high
as 4% has been documented 3 with variability attributed to
differences to the years of the studies published and changing
identification of the disease and management of risk factors
contributing to CUA development. This is a serious condition, which can cause life-threatening infections or organ
failure when left untreated. Historically, CUA is associated
with an overall poor prognosis and a mortality rate per year
ranging between 64% and 80%. The mortality rate has likely
decreased in the past decade due to treatment with sodium
thiosulfate (STS), which has been adopted as standard of care
without evidence derived from large trials.1 STS is regarded
by many to be a benign treatment, with nausea, vomiting, and
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abdominal pain as the most frequent side effects.1 There is
emerging evidence that a minority of patients may unpredictably experience metabolic acidosis with a very high anion
gap, resulting in delirium, weakness, or cardiac arrhythmia.4
Here, we describe a metabolic acidosis that developed after
STS infusion and review the literature to provide a potential
explanation.
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CA S E RE P O RT

A 68-year-old Caucasian woman with end-stage renal disease on dialysis was admitted to our facility for a stroke
and a non-ST segment elevation myocardial infarction. The
stroke caused a right facial droop and right upper extremity flaccid paralysis, without any other sensory or cognitive
disturbances. Her chronic medical conditions included type
2 diabetes mellitus (20-year history, hemoglobin A1C 6.6%
on admission), atherosclerotic coronary vascular disease,
ischemic cardiomyopathy with an ejection fraction of 35%,
congestive heart failure, paroxysmal atrial fibrillation on
warfarin anticoagulation, hypertension, and hyperlipidemia.
She had been receiving dialysis for 2 months and was anuric.
TABLE 1

Concurrently, she was found to have tender, nonhealing, necrotic, violaceous, ulcerating plaques of her right shin and
left posterior calf, which were evaluated by dermatology and
thought to be consistent with CUA. Biopsies were not obtained due to supratherapeutic INR and concern for inability
to heal from biopsy. Antibiotics (clindamycin, later changed
to vancomycin) were initiated. Blood pressure and rate control therapies with beta-blockers were initiated to mitigate
myocardial demand ischemia. She was beyond the time range
for thrombolytic therapy, but her neurologic symptoms did
not progress under observation.
The patient continued her scheduled intermittent hemodialysis (dialysate of 4 mEq/L potassium, 2.5 mEq/L calcium,
and 35 mEq/L bicarb, duration of therapy 4 hours, ultrafiltration 3 kg) on the day of her admission after medical stabilization. During the last hour of the dialysis session that
evening, 25 g of STS was also administered intravenously
to treat her CUA ulcers. The morning following, the patient
was found to have delirium, hypotension, and a metabolic acidosis with an elevated anion gap (Table 1). ABG revealed
a primary metabolic acidosis with an increased anion gap,
mixed with metabolic alkalosis with full respiratory compensation. Lactate and β-hydroxybutyrate were not elevated.

Relevant laboratory values during admission
Admission
(Hospital Day 0)

Post-STS infusion
(Hospital Day 1)

pH Arterial

7.35

7.33

Not tested

pCO2 Arterial

41

31

Not tested

Lactate (mmol/L)

2.6

2.7

Not tested
135

Sodium (mEq/L)

134

139

Potassium (mEq/L)

4.7

4.8

Chloride (mEq/L)

91

88

Hospital Day 2

Hospital Day 3

After Stabilization
(Hospital Day 4)

4.5
90

HCO3 (mEq/L)

20

14

21

Anion Gap

23

38

20

Corrected Anion Gap

24.5

39.75

Blood Urea Nitrogen
(mg/dL)

58

30

Creatinine (mg/dL)

5.41

3.98

N/A
45
3.20

Calcium (mg/dL)

9.1

9.7

7.2

Phosphorus (mg/dL)

3.9

5.5

5.0

β-Hydroxybutyrate
(mmol/L)

NA

2.31

1.84

Alkaline Phosphatase
(mg/dL)

105

92

Not tested

Aspartate Transaminase
(U/L)

41

33

Not tested

Alanine Transaminase
(U/L)

13

12

Not tested

Albumin (gm/dL)

3.4

2.9

Not tested
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Sepsis was suspected; however, three sets of blood cultures
were obtained and revealed no growth, and helical computed
tomography scan of chest, abdomen, and pelvis revealed no
nidus of infection. Her metabolic acidosis with anion gap did
not resolve despite daily dialysis with dialysate of 35 mEq/L
bicarb and stabilized with a supplemental bicarbonate drip;
her anion gap trended downward over the next 4 days and
eventually returned to her baseline.
After investigations for potential sepsis, ketosis, lactic acidosis, and uremia, STS was considered to be the probable
instigating drug in her metabolic derangement. Due to the
life-threatening nature of this profound anion gap academia,
the clinical team discontinued STS. She was treated conservatively with the help of our wound care team.
Without STS therapy, her ulcers continued to worsen. She
was judged to not be a candidate for surgical debridement
due to her multiple comorbidities. Her hospital stay was complicated by poor nutrition, health care-associated pneumonia,
and a Clostridium difficile infection. Thirty days into her
hospital stay, she elected to switch to hospice care and died
shortly thereafter.
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D IS C U SSION

Since its first described use in 2004 for CUA, STS been used
more frequently, becoming the first-line choice of treatment
for this condition, which has been known in the community
for its high morbidity.1,5 Still, despite its longtime use in the
medical and industrial domains, we understand relatively
little about its pharmacodynamic effects in the body. In the
literature, two types of acidosis produced by STS administration are described: one, a dose-dependent, mild and asymptomatic acidosis present in most patients on STS therapy6 and
another, a severe, life-threatening acidosis out of proportion
with the expected acid load of STS.4 Here, we discuss the
known pharmacology of STS and discuss the properties of
hydrogen sulfide, a metabolite of STS, that may play an additional role in both STS efficacy and side effects.7
In healthy patients, STS is excreted renally and hepatically
in equal proportions.8 Previously, a component of biliary excretion based on canine models was reported, but that does
not seem to be present in humans.9 A half-life of 3 hours
or more in healthy subjects has been cited previously,9 but
newer investigations do not support this figure. 8 Total body
clearance of STS occurs at a rate of 4.1 and 2.04 mL/min/
kg in healthy subjects and chronic hemodialysis subjects,
respectively.8 Based on these estimates, the higher plasma
concentrations needed for optimal calcium chelation are sustained for about 25 minutes in subjects with ESRD, when
STS is given after dialysis.8 The fast rate of plasma clearance
implies that the effect of STS on chelating vascular calcification is perhaps less important than initially thought or that the
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by-products of its metabolism are more therapeutically active
than STS itself.
Supporting the role of metabolic by-products are some in
vitro studies with mouse models that explore the dynamics of
calcium homeostasis in adipocytes and vascular smooth muscle cells.10 In high-phosphate environments, as is seen with
ESRD, adipocytes can start to express similar gene profiles
to osteoclasts, leading to a phenotype change leading to cellular calcification.10 Further, adipocytes induce calcification
of nearby vascular beds through upregulated VEG-A. This
effect in a high-phosphorus environment can be dampened
by the administration of STS, leading to a reduction in adipocyte phenotype changes and nearby vascular calcification for
at least 3 days.10 This effect contrasts the found half-life of
STS itself, suggesting that a metabolite impacts transcription
factor expression to mitigate calcification in the tissues.
In addition to formation of calcium thiosulfate via chelation and its effects on paracrine signaling, STS is thought
to restore endothelial homeostasis by increasing nitric oxide
synthase activity and regenerating glutathione.1 This multifactorial activity is perhaps responsible for the rapid response
in pain control some patients experience, as their ability to
vasodilate is restored before calcium homeostasis.11 The
exact biochemical pathways of the reactions facilitated by
STS remain uncharacterized, but they may be in part through
the action of hydrogen sulfide, whose effects on glutathione,
nitric oxide, and vasodilation pathways are already known.7
Endogenous thiosulfate has been hypothesized to act as a
precursor for hydrogen sulfide to maintain homeostasis, and
multiple enzymes in multiple tissue types facilitate the reaction from thiosulfate to hydrogen sulfide,12,13 but the exact reaction under physiologic conditions remains uncharacterized.
Hydrogen sulfide is a key messenger in various pathways
that coordinate the hypoxic vasodilation/vasoconstriction of vascular beds.7 It also can induce angiogenesis and independently
protect cells from ischemia.7 In ESRD, endogenous levels of hydrogen sulfide are reduced, possibly affected by reactive oxygen
species or uremia,14 but restoring hydrogen sulfide balance does
not seem to be an active focus of patient care in ESRD.
In the case of severe, unexpected, and disproportionate metabolic acidosis, perhaps hydrogen sulfide can also be implicated. The toxicity of hydrogen sulfide was first discovered in
accidental exposures of sewer workers to pockets of gas. With
exposure, patients may experience mucosal irritation, pulmonary edema, loss of consciousness, and sometimes death.15
Mucosal irritation and pulmonary edema are seemingly related to direct gas exposures, and loss of consciousness and
death are the results of excess sulfide in the blood.15 Excess
hydrogen sulfide can inhibit oxidative phosphorylation, causing a shortage of ATP, ischemia, and profound lactic acidosis,
an effect that can be quickly fatal when inhaled in high concentrations especially when combined with hypoxia.7,16 When
dissolved in the tissues in high concentrations, it inhibits the
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mitochondrial cytochrome complex IV in addition to directly
causing profound sulfide-generated oxidative stress. 16 This effect contrasts its ability to reduce oxidative stress in lower concentrations by downregulating pro-ROS forming enzymes.7
While many people can receive 25 g of STS safely, perhaps
there is a patient-specific idiosyncratic reaction, such as a metabolic phenotype or a drug interaction, that we have not yet
characterized. Further investigation into the pharmacokinetics
of hydrogen sulfide and its behavior in ESRD is needed.
When thinking about our patient and the others with dangerous acidemia, it is still unknown why these events occur. With
our current understanding of thiosulfate, hydrogen sulfide, and
the physiology of ischemia, there are several possibilities: (1)
the acid formed from thiosulfate becoming thiosulfuric acid in
an aqueous solution during administration; (2) the direct hydrogen load of hydrogen sulfide; (3) lactic acid accumulation
from ATP production inhibition; (4) an insurmountable oxidative stress from sulfide-containing compounds; and (5) a rare
phenotype that makes the above more likely to occur.
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CO NC LU SION

As STS use in ESRD populations increases, we are beginning to characterize side effects of STS, which include a mild
acidosis from the administration of an acidic compound and a
distinctly different and more extreme acidosis with an anion
gap out of proportion with the acid load of the drug itself. We
do not know why this reaction occurs in some patients or what
the predisposing factors may be, but metabolites of STS may
be responsible. Hydrogen sulfide is a ubiquitous inorganic
compound in the body and has known effects on vascular inflammation and oxygen delivery. While still unexplored, the
breakdown of thiosulfate to hydrogen sulfide may be responsible for the drug’s efficacy. Similarly, the toxicity profile of hydrogen sulfide, as seen in accidental occupational exposures,
may provide some clues as to why some patients develop profound metabolic acidosis. More research is needed into finding
the cause of such a dangerous idiosyncratic reaction.
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